Nordic Nanovector’s lead product candidate, Betalutin®, is a first-in-class Antibody-Radionuclide-Conjugate (ARC) that aims to prolong the survival and improve the quality of life of patients who suffer from non-Hodgkin Lymphoma (NHL), a life-threatening blood cancer with a high unmet medical need.

Betalutin® has been specifically designed to provide an alternative and complementary therapeutic mechanism of action to existing treatments for NHL. Betalutin® is undergoing clinical development as a potential new treatment of relapsed NHL.